I’m sure it comes as no surprise to anyone reading this article that we have a problem in drug development. Pharmaceutical companies are having to...

Rare diseases by definition only affect a small number of people, but rare disease studies can reveal valuable information for more common...

This article discusses how the pharmaceutical industry can leverage its competencies in outsourcing to accelerate time to market, improve quality...

Recently, Oxbridge Biotech Roundtable (OBR) interviewed Scientist’s Kevin Lustig about how his career decisions and approach to research shaped his...

It’s not hard to find articles, blog posts, or market reports these days that state contract research organizations, and outsourcing in general, is...

Last month we ran a series of blog posts about next generation sequencing. Among the topics discussed were the limitations of next generation...

We’ve covered many different aspects of pharmaceutical innovation, ranging from organizational structure, patents, and incubators, but are there...

Although pharmaceutical companies and contract research organizations operate in the same preclinical drug discovery space, working for the two...

Here at Scientist, for the past few weeks we’ve been running a series of blog posts about stem cells discussing why iPS make an attractive research...

In the field of synthetic chemistry, the “elephant in the room” is that chemists spend most of their time just trying to reproduce published...